Angiogenèse
Les inhibiteurs de l'angiogenèse sont des composés qui interfèrent avec la formation de nouveaux vaisseaux sanguins, un processus crucial dans la croissance et la métastase des cancers. En inhibant l'angiogenèse, ces composés peuvent restreindre l'apport sanguin aux tumeurs, ralentissant ou arrêtant leur croissance. Les inhibiteurs de l'angiogenèse sont essentiels dans la recherche sur le cancer et le développement thérapeutique, offrant des informations sur les mécanismes de progression tumorale et proposant des traitements potentiels pour le cancer et d'autres maladies liées à l'angiogenèse. Chez CymitQuimica, nous offrons une large gamme d'inhibiteurs de l'angiogenèse de haute qualité pour soutenir vos recherches en oncologie et biologie vasculaire.
Sous-catégories appartenant à la catégorie "Angiogenèse"
- BTK(147 produits)
- Bcr-Abl(103 produits)
- EGFR(572 produits)
- FAK(71 produits)
- FLT(91 produits)
- Récepteur du facteur de croissance des fibroblastes (FGFR)(169 produits)
- JAK(246 produits)
- PDGFR(126 produits)
- RAAS(87 produits)
- Src(80 produits)
- Syk(37 produits)
- Thrombine(47 produits)
- VDA(2 produits)
- VEGFR(262 produits)
Affichez 6 plus de sous-catégories
1522 produits trouvés pour "Angiogenèse"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Antifibrotic agent 1
<p>Antifibrotic agent 1 is an orally active medication designed to treat idiopathic pulmonary fibrosis (IPF). It effectively mitigates IPF-related processes, including TGF-β-induced epithelial-mesenchymal transition (EMT) and fibroblast-to-myofibroblast transition (FMT), as well as profibrotic M2 polarization. Antifibrotic agent 1 selectively inhibits CSF-1R, PDGFR-α, and Src family kinases (SFKs), while sparing VEGFR, FGFR, and Abl to minimize off-target toxicity. In a bleomycin (BLM)-induced pulmonary fibrosis mouse model, it demonstrates strong antifibrotic activity.</p>Formule :C27H23ClN6O2Couleur et forme :SolidMasse moléculaire :498.1571JAK1/TYK2-IN-1
CAS :<p>JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 ( IC 50 = 29 and 41 nM respectively).</p>Formule :C18H20F3N7OCouleur et forme :SolidMasse moléculaire :407.401OK2
<p>OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.</p>Formule :C42H62N14O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :907.03DB1113
CAS :DB1113 is a bifunctional kinase degrader, targeting ABL1, ABL2, CDK4, MAPKs, and more for disease research.Formule :C59H68F3N13O6SCouleur et forme :SolidMasse moléculaire :1144.31SOS1/EGFR-IN-2
<p>SOS1/EGFR-IN-2 (Compound 4) functions as a dual inhibitor of SOS1 and EGFR, exhibiting IC50 values of 8.3 and 14.6 nM, respectively. It demonstrates significant antiproliferative effects on cancer cells harboring various KRAS mutations.</p>Formule :C25H29F3N4O3Couleur et forme :SolidMasse moléculaire :490.52FLT3/VEGFR2-IN-1
FLT3/VEGFR2-IN-1 (Compound 26) is a potent inhibitor of FLT3, VEGFR2, and HDAC, exhibiting IC50 values of 14.5 nM, 3.9 nM, and 30.8 nM against FLT3, VEGFR2, and HDAC1, respectively. It effectively inhibits the phosphorylation of STAT3 and ERK1/2, as well as the proliferation of leukemia cells. FLT3/VEGFR2-IN-1 demonstrates antitumor activity and is applicable in research on acute myeloid leukemia.Formule :C29H35N7O5Couleur et forme :SolidMasse moléculaire :561.63PROTAC EGFR degrader 7
<p>Compound 13b, a potent EGFR degrader, inhibits and induces apoptosis in NSCLC cells with a DC50 of 13.2 nM.</p>Formule :C46H48N10O6Couleur et forme :SolidMasse moléculaire :836.94Pomalidomide-C5-Dovitinib
CAS :<p>Pomalidomide-C5-Dovitinib (compound 2) is a PROTAC that links Pomalidomide and Dovitinib via a CRBN connector, exhibiting potent antiproliferative activity in</p>Formule :C39H38FN9O6Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :747.77DSPE-PEG1000-A7R
<p>DSPE-PEG1000-A7R is a PEG compound consisting of DSPE and the tumor vasculature-targeting peptide (A7R). A7R exhibits high affinity and specificity for VEGFR-2, which is overexpressed in various tumors.</p>Couleur et forme :Odour SolidEGFR/CDK2-IN-2
<p>EGFR/CDK2-IN-2 (compound 6a) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 19.6 nM and 87.9 nM, respectively.</p>Formule :C49H32N12O2S2Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :884.99FAK-IN-27
<p>FAK-IN-27 (compound 8A) is a potent and selective inhibitor of FAK, with an IC50 of 4.968 nM. It effectively inhibits the proliferation of H1299 cells, with an IC50 of 0.28 μM, and is applicable for research in non-small cell lung cancer (NSCLC).</p>Formule :C32H28ClN5O6Couleur et forme :SolidMasse moléculaire :613.17281YH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Couleur et forme :Odour LiquidJAK-IN-15
CAS :<p>JAK-IN-15 is a JAK inhibitor. WO2016119700A1 (Compound 15).</p>Formule :C22H23FN4O3SCouleur et forme :SolidMasse moléculaire :442.51Anti-ERBB3/HER3 (29Z6)
<p>Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor targeting human ERBB3/HER3.</p>Couleur et forme :Odour LiquidCOVA208
<p>COVA208 is a bispecific FynomAb targeting HER2, consisting of a fusion protein of an antibody and a FynSH3-derived binding protein. It induces the degradation of HER2, reducing the levels of HER2, HER3, and EGFR, effectively blocking downstream signaling pathways such as HER3-PI3K-AKT and MAPK, and inducing apoptosis in tumor cells. COVA208 shows promise for research in cancers like HER2-positive breast, gastric, and colorectal cancers.</p>Couleur et forme :Odour LiquidEGFR/CDK2-IN-3
<p>EGFR/CDK2-IN-3 (compound 4b) serves as a dual inhibitor targeting both EGFR and CDK-2, exhibiting IC50 values of 71.7 nM and 113.7 nM, respectively.</p>Formule :C30H20N6OSDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :512.58IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Couleur et forme :Odour LiquidIMC-D11
<p>IMC-D11 (LY-3076226 antibody) is an IgG1 monoclonal antibody targeting FGFR3. It serves as the antibody component of LY3076226. For its isotype control, refer to Human IgG1 kappa, Isotype Control.</p>Couleur et forme :Odour LiquidABP-102
<p>ABP-102 (CT P72) is a bispecific t-cell adduct (BiTE) that acts as a CD3 modulator and selective HER2 modulator for targeting HER2 overexpressing tumors.</p>Couleur et forme :Odour LiquidVEGFR2/HDAC1-IN-1
<p>VEGFR2/HDAC1-IN-1 (compound 13) is a potent dual inhibitor of VEGFR-2 and HDAC, with IC50 values of 57.83 nM for VEGFR-2 and 9.82 nM for HDAC.</p>Degré de pureté :98%Couleur et forme :Odour Solid
